Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MNOV
stocks logo

MNOV

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for MediciNova Inc (MNOV.O) is -3.96, compared to its 5-year average forward P/E of -8.09. For a more detailed relative valuation and DCF analysis to assess MediciNova Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.09
Current PE
-3.96
Overvalued PE
-2.20
Undervalued PE
-13.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
1.78
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
9.10
Undervalued EV/EBITDA
-5.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
35.58
Current PS
0.00
Overvalued PS
117.66
Undervalued PS
-46.51
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MNOV News & Events

Events Timeline

(ET)
2025-11-18
06:07:50
MediciNova appoints Dr. Christopher Breder as Advisor for Clinical and Regulatory Affairs
select
2025-11-04 (ET)
2025-11-04
07:37:41
MediciNova finishes enrolling patients for the MN-001-NATG-202 trial
select
2025-10-30 (ET)
2025-10-30
20:50:27
MediciNova's Compounds Show Innovative Treatment Strategy for Atherosclerosis
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-02Globenewswire
MediciNova Unveils Novel Mechanism for MN-001 Enhancing Cholesterol Efflux
  • Research Breakthrough: A study in collaboration with a leading Japanese academic team reveals that MN-002 enhances cholesterol efflux in macrophages by upregulating ABCA1 and ABCG1 transporters, a critical mechanism for Reverse Cholesterol Transport that helps clear cholesterol from arterial walls, thereby reducing the risk of atherosclerosis and cardiovascular diseases.
  • Clinical Progress: MediciNova has completed patient enrollment for its Phase 2 trial of MN-001 in patients with hypertriglyceridemia and type 2 diabetes, with top-line results expected by summer 2026, which will provide crucial data to advance MN-001 as a potential first-in-class therapy.
  • Multi-Indication Potential: The multi-modal activity of MN-001, including anti-inflammatory and anti-fibrotic properties, positions it uniquely for treating metabolic disorders such as hypertriglyceridemia, non-alcoholic fatty liver disease, and type 2 diabetes, potentially leading to significant improvements in patients' lipid profiles.
  • Strategic Implications: The research findings provide strong scientific validation for the lipid profile improvements observed in previous clinical studies of MN-001, further reinforcing its potential to address multiple interconnected metabolic disorders, indicating MediciNova's capability for long-term value creation in the biopharmaceutical sector.
[object Object]
Preview
3.5
12-02Newsfilter
MediciNova Unveils Novel Mechanism for MN-001 Enhancing Cholesterol Efflux
  • Research Breakthrough: A study conducted in collaboration with a leading Japanese academic team reveals that MN-002 enhances cholesterol efflux in macrophages by upregulating ABCA1 and ABCG1 transporters, a critical mechanism for Reverse Cholesterol Transport, which is essential for clearing cholesterol from arterial walls and reducing the risk of atherosclerosis and cardiovascular diseases.
  • Clinical Progress: MediciNova has completed patient enrollment in its Phase 2 trial for MN-001 targeting hypertriglyceridemia and NAFLD due to type 2 diabetes, with top-line results expected by summer 2026, which will provide crucial data to support MN-001's advancement as a potential first-in-class therapy.
  • Multi-modal Efficacy: MN-001's unique multi-modal activity, including anti-inflammatory and anti-fibrotic properties, positions it distinctively among emerging therapies, enabling it to address multiple interconnected metabolic disorders such as hypertriglyceridemia, NAFLD, and type 2 diabetes, showcasing its broad therapeutic potential.
  • Strategic Implications: The mechanistic insights from this research provide strong scientific validation for the lipid profile improvements observed in previous clinical studies, further solidifying MN-001's strategic position in the treatment of metabolic and cardiovascular diseases, and is expected to create long-term value for shareholders.
[object Object]
Preview
5.0
11-18Newsfilter
MediciNova Names Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Consultant

  • Appointment of Dr. Breder: MediciNova, Inc. has appointed Dr. Christopher D. Breder as Clinical and Regulatory Advisor to guide its drug development programs and lead the Scientific Advisory Board.

  • Dr. Breder's Expertise: With over 20 years of experience at the FDA and in the pharmaceutical industry, Dr. Breder specializes in regulatory strategy and clinical trial design, particularly for neurological conditions.

  • MediciNova's Pipeline: The company is focused on developing novel therapies for neurodegenerative diseases, with its lead asset, MN-166 (ibudilast), currently in Phase 3 trials for ALS and other conditions.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding the development and efficacy of MediciNova's drug candidates, highlighting potential risks and uncertainties in clinical trials and regulatory approvals.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is MediciNova Inc (MNOV) stock price today?

The current price of MNOV is 1.55 USD — it has increased 2.65 % in the last trading day.

arrow icon

What is MediciNova Inc (MNOV)'s business?

MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.

arrow icon

What is the price predicton of MNOV Stock?

Wall Street analysts forecast MNOV stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNOV is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is MediciNova Inc (MNOV)'s revenue for the last quarter?

MediciNova Inc revenue for the last quarter amounts to 123.32K USD, decreased % YoY.

arrow icon

What is MediciNova Inc (MNOV)'s earnings per share (EPS) for the last quarter?

MediciNova Inc. EPS for the last quarter amounts to -0.06 USD, decreased -0.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for MediciNova Inc (MNOV)'s fundamentals?

The market is revising No Change the revenue expectations for MediciNova, Inc. (MNOV) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 20.16%.
arrow icon

How many employees does MediciNova Inc (MNOV). have?

MediciNova Inc (MNOV) has 13 emplpoyees as of December 05 2025.

arrow icon

What is MediciNova Inc (MNOV) market cap?

Today MNOV has the market capitalization of 75.78M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free